The publisher explores Bayer’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (4 November 2020)
Model updates (5 August 2020)
Model updates (26 April 2020)
Model updates (26 February 2020)
Snapshot
- Overview - Bayer’s prescription drug sales will experience modest growth over the forecast period.
- Key themes - [1] Xarelto and Eylea, Bayer’s two flagship drugs, will see robust global growth in the short term [2] Growth in China is key for several of Bayer’s franchises [3] Genitourinary remains a key therapy area, as Yaz and Mirena will drive sales growth.
Model updates (4 November 2020)
- Eylea forecast adjusted higher due to less COVID-19 impact and revision of generic launch timing
- Xarelto forecast adjusted higher due to strong performance globally.
Model updates (5 August 2020)
- Adalat forecast adjusted lower due to COVID-19 impact
- Gadavist forecast adjusted lower due to COVID-19 impact
- Glucobay forecast adjusted lower due to volume-based procurement policy in China
- Kogenate forecast adjusted higher due to sales
- Mirena forecast adjusted lower due to COVID-19 impact
- Vericiguat forecast pulled forward due to registration in Europe and Japan.
Model updates (26 April 2020)
- Xarelto forecast adjusted higher due to higher volumes globally and stable performance in the US
- Glucobay forecast adjusted lower due to COVID-19 impact in China
- Jivi forecast removed due to Bayer consolidating Jivi sales with Kogenate.
Model updates (26 February 2020)
- Eylea forecast adjusted higher due to continued strength in Europe, Japan, and the Middle East
- Betaferon/Betaseron forecast adjusted lower due to continued market share losses in the US.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview
